BridgeMD
A pharmacokinetics and safety study of cefiderocol in hospitalized pediatric patients from birth to less than 3 months of age with suspected or confirmed Gram-negative bacterial infections
EU CTIS ID: 2023-503757-35-00
What this study is testing
1. To assess the PK of cefiderocol after single-dose administration in hospitalized pediatric patients from birth to < 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections, including but not limited to, cUTI, cIAI, HABP/VABP, and BSI/sepsis 2. To assess the PK of cefiderocol after multiple-dose administration in hospitalized pediatric patients from birth to < 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections, including but not limited to, cUTI, cIAI, HABP/VABP, and BSI/sepsis
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Written informed consent has been provided by parent(s) or legally authorized representative(s) (LAR) in accordance with local regulatory requirements
- Hospitalized infants from birth to < 3 months (< 90 days) of age at the time written informed consent is provided. Enrollment of premature infants will not be restricted, but they must have a GA ≥ 26 weeks, PNA of 0 to 3 months, and weight of at least 1 kg.
- Require systemic IV antibiotic treatment for suspected or confirmed aerobic Gram-negative infections, including but not limited to, cUTI, cIAI, HABP/VABP, and BSI/sepsis
- For the multiple-dose phase, within 72 hours of the start of potentially effective treatment with SOC antibiotics for the suspected or confirmed primary Gramnegative infection
You likely can't join if
- Documented history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibiotic (Note: for β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment)
- Receiving treatment with a vasopressor at Screening
- Confirmed or strongly suspected infection at Screening with a pathogen known to be resistant to cefiderocol or only a Gram-positive pathogen or viral, fungal, or parasitic pathogen as the sole cause of infection
- Anticipated need for antibacterial therapy longer than 14 days (eg, osteomyelitis or endocarditis); this applies to both study treatment with cefiderocol, as well as adjunctive IV antibacterial treatment for suspected coinfection with Gram-positive organisms or multidrug resistant Gram-negative organisms
- Suspected or confirmed central nervous system (CNS) infection, including patients with suspected CNS infection who do not have a lumbar puncture (LP) but who are treated for potential CNS infection, patients who have evidence suggestive of CNS infection based on LP results (polymorphonuclear pleocytosis, hypoglycorrhachia, and increased protein concentration), regardless of culture results, and patients with a LP with organisms on Gram stain or culture-positive CSF
- Life expectancy of < 72 hours after enrollment
See the full eligibility criteria
- Written informed consent has been provided by parent(s) or legally authorized representative(s) (LAR) in accordance with local regulatory requirements
- Hospitalized infants from birth to < 3 months (< 90 days) of age at the time written informed consent is provided. Enrollment of premature infants will not be restricted, but they must have a GA ≥ 26 weeks, PNA of 0 to 3 months, and weight of at least 1 kg.
- Require systemic IV antibiotic treatment for suspected or confirmed aerobic Gram-negative infections, including but not limited to, cUTI, cIAI, HABP/VABP, and BSI/sepsis
- For the multiple-dose phase, within 72 hours of the start of potentially effective treatment with SOC antibiotics for the suspected or confirmed primary Gramnegative infection
- Documented history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibiotic (Note: for β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment)
- Receiving treatment with a vasopressor at Screening
- Confirmed or strongly suspected infection at Screening with a pathogen known to be resistant to cefiderocol or only a Gram-positive pathogen or viral, fungal, or parasitic pathogen as the sole cause of infection
- Anticipated need for antibacterial therapy longer than 14 days (eg, osteomyelitis or endocarditis); this applies to both study treatment with cefiderocol, as well as adjunctive IV antibacterial treatment for suspected coinfection with Gram-positive organisms or multidrug resistant Gram-negative organisms
- Suspected or confirmed central nervous system (CNS) infection, including patients with suspected CNS infection who do not have a lumbar puncture (LP) but who are treated for potential CNS infection, patients who have evidence suggestive of CNS infection based on LP results (polymorphonuclear pleocytosis, hypoglycorrhachia, and increased protein concentration), regardless of culture results, and patients with a LP with organisms on Gram stain or culture-positive CSF
- Life expectancy of < 72 hours after enrollment
- Urine output < 1.0 mL/kg/hour within the 24 hours prior to study drug administration on Day 1
- Serum creatinine value greater than the maximum for GA and PNA shown in the Protocol within the 24 hours prior to study drug administration on Day 1
- Neonatal acute kidney injury (AKI), defined as a serum creatinine level greater than 1.5 mg/dL (133 μmol/L) or an increase of 0.3 mg/dL (17 to 27 μmol/L) per day from a previous lower value
- Acute kidney injury based on an increase in serum creatinine ≥ 0.3 mg/dL within 48 hours from an established baseline value
- Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the study data
- Receiving renal replacement therapy
- Received any other investigational medicinal product within 30 days of study drug administration
The study team makes the final eligibility decision.
Where it's taking place
- Israel
- Vietnam
- Taiwan
- United States
- South Africa
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Israel; Vietnam; Taiwan; United States; South Africa. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.